OS Therapies Inc (OSTX) · Oct 19, 2026 · Share issuance
$7.2M financing — $7.2M gross; 5.52M shares and 5.52M new warrants
OS Therapies’ financing adds $7.2M for Herlystic regulatory work, but pairs every exercised warrant with a new five-year warrant.
OS Therapies is a clinical-stage oncology company trying to move Herlystic from positive Phase 2b data toward U.S., U.K., European and Australian regulatory submissions, with Q4 2026 filings already part of the standing plan. Recent company updates continue to frame the business around regulatory and commercial preparation for Herlystic rather than near-term product revenue.
The financing advances that regulatory push, but it is not a clean capital raise. Seven of nine eligible holders exercised or pre-funded warrants for 5,517,253 shares and generated $7.2 million of gross proceeds before fees and expenses. The proceeds are earmarked for regulatory filings, commercial preparation and general corporate purposes.
| Item | Filing figure or term |
|---|---|
| Gross proceeds | $7.2 million (Press Release) |
| Shares issued or pre-funded | 5,517,253 (Press Release) |
| Inducement exercise price | $1.30 per share; $1.299 for pre-funding (Press Release) |
| New warrants issued | Up to 5,517,253 shares (Press Release) |
| New warrant exercise price and term | $1.40 per share; five years (Material Contract) |
| R&D tax credits accrued | $7 million, expected in early 2027 (Press Release) |
| Solicitation fee | 7.0% of gross proceeds plus $25,000 expense allowance (Material Contract) |
The trade-off is meaningful dilution overhang, not just headline dilution. For each exercised or pre-funded share, OS Therapies issued a new warrant for an equivalent number of shares at $1.40, immediately exercisable and valid for five years. That gives the company cash now, but preserves a large block of potential future share issuance and required a new resale registration statement by November 30, 2026.
The event is partly new funding and partly confirmation of an established financing pattern. OS Therapies has repeatedly used warrant inducements to extend funding for Herlystic’s regulatory path, so the direction was already familiar; the initial closing confirms seven holders participated and puts fresh cash behind the Q4 submission target. The $7 million U.K. tax credit is another potential funding source, but it remains accrued rather than received, with filing expected in Q4 2026 and cash expected in early 2027.
Bottom line: This keeps Herlystic’s regulatory program financed into its next milestone, but the money comes with matching warrants and additional future dilution. It is operationally helpful, though not a clean positive surprise because the company is still relying on serial warrant-driven funding and an unreceived tax credit to support the path forward.
Q4 2026 BLA and CMAA submissions
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!